Diltiazem, Direct Oral Anticoagulants and Risk of Major Bleeding in Patients with Atrial Fibrillation AHA Conference Repository

American Heart Association

156

Final ID: Sa2078

Diltiazem, Direct Oral Anticoagulants and Risk of Major Bleeding in Patients with Atrial Fibrillation

Abstract Body (Do not enter title and authors here):
Background
Existing research suggests a potential increase in bleeding risk associated with the combined use of calcium channel blockers (CCBs) and direct oral anticoagulants (DOACs). However, the evidence remains inconclusive and conflicting. To clarify this relationship, we conducted a meta-analysis to investigate the risk of major bleeding in patients with atrial fibrillation (AF) using diltiazem.
Methods
We conducted a comprehensive search of major electronic databases, including PubMed, Embase, and the Cochrane Library, from their inception through April 20, 2024 for relevant studies. The primary endpoint was major bleeding, defined as a composite of bleeding-related hospitalization, requiring blood transfusion, or fatal bleeding. We conducted a conventional meta-analysis using the Hartung-Knapp-Sidik-Jonkman random-effects model. Endpoints are expressed as hazard ratio (HR) and their corresponding confidence intervals (CI).
Results
A total of 5 studies with 488,884 patients with AF were included in our study, of which 23.4% of patients were on diltiazem. All patients were also on DOACs. Results of the meta-analysis showed that there was no statistically significant difference between use of diltiazem and the risk of major bleeding (HR 1.16 ; 95% CI 0.94-1.42). Sensitivity analysis showed that this result remained unaltered in terms of magnitude and direction after excluding one study at a time. When stratified by type of control group, both active comparator (HR 1.09 ; 95% CI 0.92-1.30) and non-use subgroups (HR 1.24 ; 95% CI 0.87-1.77) showed that there was no significant difference in the risk of major bleeding with diltiazem use respectively.
Conclusion
We observed that there was no significant difference in the risk of major bleeding in diltiazem use compared to controls in AF patients on DOACs. Further large-scale, longitudinal, and prospective studies are essential to validate these findings.

Chia, Jia Ee ( Internation Medical University , Kla , Malaysia )
Ang, Song Peng ( Rutgers Health CMC , Toms River , New Jersey , United States )
Krittanawong, Chayakrit ( NYU Langone Health , New York , New York , United States )
Patel, Shreya ( Touro School of Osteopathic Medicine , New York , New York , United States )
Mukherjee, Debabrata ( Texas Tech University , El Paso , Texas , United States )

Author Disclosures:

Jia Ee Chia:

DO NOT have relevant financial relationships

Song Peng Ang:

DO NOT have relevant financial relationships

Chayakrit Krittanawong:

No Answer

Shreya Patel:

DO NOT have relevant financial relationships

Debabrata Mukherjee:

DO NOT have relevant financial relationships

Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Atrial Fibrillation Comparative Data on Medical Therapies and Anticoagulation

Saturday, 11/16/2024 , 10:30AM - 11:30AM

Abstract Poster Session

More abstracts from these authors:

Trends and Disparities of Ischemic Stroke–Related Mortality Among the Young Adults in the United States from 1999-2020

Chia Jia Ee, Ang Song Peng, Mukherjee Debabrata

Trends, Outcomes and Predictors of Mortality in Patients with Myeloproliferative Neoplasms Undergoing Percutaneous Coronary Intervention: Insights from National Database

Ang Song Peng, Chia Jia Ee, Krittanawong Chayakrit, Misra Kanchan, Jaiswal Vikash, Song David, Usman Mohammed Haris, Piana Robert, Mukherjee Debabrata

American Heart Association

Diltiazem, Direct Oral Anticoagulants and Risk of Major Bleeding in Patients with Atrial Fibrillation

Meeting Info:

Session Info:

More abstracts on this topic:

More abstracts from these authors: